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Objectives. This study sought o assess the clinical character- 
istics and survival of patients with symptomatic heart failure who 
were referred as potential heart ransplant candidates, but were 
selected for medical management. 
Background. Patients with severe left ventricular dysfunction 
referred for heart ransplantation may be considered too well to 
be placed immediately on an active waiting transplant list. The 
clinical characteristics of this patient group and their survival 
have not been well defined. These patients represent a unique 
group that are characterized by comparatively ow age and 
freedom from significant comorbid conditions. 
Methods. We studied 116 consecutive patients with symptom- 
atic heart failure, severe left ventricular dysfunction (left ventric- 
ular ejection fraction 20 -+ 7% [mean _+ SD]) and duration of 
symptoms >1 month referred for heart ransplantation, who were 
acceptable candidates for the procedure but who were not listed 
for transplantation because of relative clinical stability. These 
patients were followed up closely on optimal medical therapy. A 
variety of baseline clinical, hemodynamic and exercise variables 
were assessed to define this patient group and used to predict 
cardiac death and requirement later for heart ransplantation. 
Results. During a mean follow-up eriod of 25.0 ± 14.8 months 
(follow-up 99% complete), there were eight cardiac deaths (7%) 
(seven sudden, one acute myocardial infarction). Only nine pa- 
tients (8%) were listed for heart ransplantation. Actuarial 1- and 
4-year cardiac survival rates were 98 +- 1% and 84 ± 7% (mean -+ 
SE), respectively, and freedom from listing for transplantation 
was 95 -+ 2% and 84 ± 7% (mean + SE), respectively. Patients 
were mainly in New York Heart Association functional class II or 
III and had a preserved cardiac index (2.4 liters/min.m2), pulmo- 
nary capillary wedge pressure of 16 -4-- 9 mm Hg (mean -+ SD) and 
maximal oxygen consumption of 17.4 _+ 4.3 m[/min per kg 
(mean + SD). By logistic regression analysis, there was no 
predictor for cardiac death. Longer duration of heart failure (p = 
0.013) and mean pulmonary artery (p < 0.05) and pulmonary 
systolic (p = 0.014) and diastolic (p < 0.05) pressures correlated 
significantly with listing for heart transplantation by univariate 
logistic regression. By multivariate logistic regression, only pul- 
monary artery systolic pressure (p < 0.004) and duration of heart 
failure (p < 0.015) remained as predictors for need for later 
transplantation. 
Conclusions. In the current reatment era, prognosis is favor- 
able in a definable group of transplant candidates despite severe 
left ventricnlar dysfunction. This patient group can be identified 
after intensive medical therapy by stable symptoms, a relatively 
high maximal oxygen uptake at peak exercise and a preserved 
cardiac output. 
(J Am Coll Cardiol 1996;27:1192-7) 
Symptomatic patients with heart failure have a poor prognosis 
(1-3). Altough treatment with vasodilators (4) and angiotensin- 
converting enzyme inhibitors have been shown (5-7) to im- 
prove outcome in patients in heart failure, mortality is still 
high, with a 6-month mortality rate of -20% to 30%. A single 
previous tudy in 30 patients with idiopathic dilated cardiomy- 
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opathy (8) reported a mortality rate of 54% at 1 year in 
patients referred but turned own for transplantation because 
of the absence of severe symptoms. These data have led to a 
large increase in the number of patients listed for heart 
transplantation. However, there are no data available in the 
current reatment era on the short- and medium-term survival 
in compliant patients, free of significant comorbid conditions, 
with stable symptoms, who are suitable candidates for heart 
transplantation based on evidence of severe left ventricular 
dysfunction. The aim of the present study was to characterize 
such a group of patients, referred to our institution for 
consideration for heart transplantation but whose symptoms 
could be stabilized, and to analyze their mortality and require- 
ment for later listing for heart transplantation during an 
extended period of aggressive medical management. Clinical, 
hemodynamic and exercise data were analyzed after prior 
stabilization at the time of initial evaluation to define this 
©1996 by the American College of Cardiologs' 0735-1097/96/$15.00 
Published by Elsevier Science Inc. SSDI 0735-1097(95)00587-0 
JACC Vol. 27, No. 5 RICKENBACHER ET AL. 1193 
April 1996:1192-7 MEDICAL TREATMENT OF TRANSPLANT CANDIDATES 
Study 
population 
;.04% 
13.33% 
24.96% 
• Patients accepted for Tx 
• -~ Pts rejected for one or more contraindications 
[ ]  Pts too sick for transplantation 
[ ]  CABG or valve replacement 
[ ]  Pts rejected for miscellaneous reasons 
[ ]  Suitable Tx candidates but stable 
Figure 1. Between January 1989 and September 1993, 645 patients 
(Pts) were referred for evaluation for heart ransplantation (Tx). One 
hundred thirty-four (21%) were suitable transplant candidates but 
were considered in sufficiently stable condition to be managed medi- 
cally. One hundred sixteen (87%) of the 134 patients formed the study 
group. CABG = coronary artery bypass graft surgery. 
patient group and to determine which factors were associated 
with subsequent mortality or for need for heart transplanta- 
tion. 
Methods 
Study patients. Between January 1989 and September 
1993, of 645 patients referred to Stanford University Medical 
Center for evaluation for heart transplantation, 226 (35%) 
were accepted for transplantation; 161 (25%) were rejected for 
one or more contraindications; 16 (3%) were too sick for 
transplantation, 22 (3%) were scheduled for coronary artery 
bypass graft surgery or valve replacement; and 86 (13%) were 
rejected for miscellaneous reasons, including referral to an- 
other hospital, incomplete evaluation, death during evaluation, 
insurance problems and patient refusal of transplantation. One 
hundred thirty-four (21%) were suitable transplant candidates 
but were considered sufficiently stable to be managed medi- 
cally (Fig 1). A further 18 patients were excluded because they 
underwent o formal evaluation at Stanford (9 patients), had 
no clinical evidence of heart failure (6 patients, including 2 
with congenital heart disease, 1with perieardial disease, 1with 
cardiac tumor) or had a duration of heart failure <1 month (1 
patient). One hundred sixteen (87%) of the 134 patients who 
had no contraindication forheart transplantation formed the 
study group. These patients had all been referred by a cardi- 
ologist for consideration for heart transplantation. Most of 
these patients had had one or more hospital admissions for 
decompensated heart failure. Their duration of heart failure 
was >1 month from idiopathic dilated cardiomyopathy, valvu- 
lar heart disease or coronary artery disease. 
The patients were not immediately isted for heart trans- 
plantation because an experienced transplant cardiologist 
(M.B.F., R.H.V. or J.S.S.), a transplant social worker and the 
patient agreed that the patient's current quality of life (after 
maximizing medical therapy) was acceptable. The baseline 
clinical criteria were measured (after initial clinical stabiliza- 
tion) to characterize this patient group. 
The initial evaluation i cluded ahistory and physical exam- 
ination in all study patients. Standardized treatment included 
angiotensin-converting e zyme inhibitors, digoxin and diuretic 
drugs, as required clinically. Further studies were performed 
after clinical stabilization of heart failure. Right-sided heart 
catheterization with a flow-directed catheter was performed in
102 patients (88%). Right atrial, pulmonary artery and pulmo- 
nary capillary wedge pressures were measured, and cardiac 
output was calculated by the Fick method. Left ventricular 
ejection fraction was determined by angiographic or radionu- 
clide ventriculography in 100 patients (86%). Peak oxygen 
consumption with breath by breath oxygen and carbon dioxide 
analysis was measured in 102 patients (88%) during symptom- 
limited maximal bicycle ergometry using a ramp protocol with 
increases in work load of 10 W/rain. Selective coronary angiog- 
raphy was performed in all patients >35 years old or when 
clinically indicated (history of chest pain or electrocardio- 
graphic changes consistent with a previous myocardial infarc- 
tion). Coronary artery disease was diagnosed inthe presence of 
>50% lumen stenosis in one or more of the major epicardial 
coronary arteries. 
Follow-up. Patients were seen by the study investigators or 
by the referring physicians at regular intervals. Patients were 
followed up until death or December 31, 1993, the cutoff date 
for this analysis. Information regarding survival or circum- 
stances of death as well as transplantation r listing for 
transplantation was obtained by chart review or telephone 
interview of patients, relatives and the referring physician. 
Three patients (1%) were lost to follow-up and were excluded 
from the analysis. 
Definitions. Cardiac deaths included sudden cardiac death, 
death from progressive heart failure and death in the setting of 
an acute myocardial infarction. Sudden death was defined as 
the unexpected death in or out of hospital within 1 h after 
onset of symptoms or during sleep in a patient who was 
symptomatically stable during the 24 h before death. Patients 
resuscitated from such an episode were considered survivors of 
sudden death. Heart failure death was defined as progressive 
hemodynamic deterioration leading to death. Patients were 
listed for transplantation if they had worsening and disabling 
symptoms despite maximal medical treatment or if they re- 
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Table 1. Baseline Characteristics of Study Patients 
Age at evaluation (yr) 46.6 --_ 10•3 
Men 88 (76) 
Women 28 (24) 
NYHA functional class 2.7 _+ 0.5 
Etiology of heart failure 
CAD 30 (26) 
IDCM 80 (69) 
Valvular heart disease 6 (5) 
Duration of heart failure 18.6 ± 21.1 
symptoms (mo) 
Treatment 
ACE inhibitors 111 (96) 
Diuretic drugs 100 (86) 
Digoxin 95 (82) 
Amiodarone 8 (7) 
Class I antiarrhythmic 12 (10) 
agents 
Hx of sustained VT/SCD 11 (10) 
Hx of nonsustalned VT 22 (19) 
Atrial fibrillation 18 (16) 
ICO 5 (4) 
LVEF 20 ± 7 
RAP (mm Hg) 6 ± 6 
PAS (ram Hg) 36 + 15 
PAD (ram Hg) 17 ± 9 
MPAP (ram Hg) 25 ± 12 
PCWP (mm Hg) 16 + 9 
Cardiac index (liter min'm 2) 2.4 + 0.8 
Max Vo2 (ml/min per kg) 17.4 _+ 4.3 
Data are expressed as mean value _+ SD or number (%) of patients• ACE - 
angiotensin-eonverting e zyme; CAD - coronary artery disease; I-Lx = history; 
ICD = implantable cardioverter-defibrillator; IDCM = idiopathic dilated car- 
diomyopathy; LVEF = left ventricular ejection fraction; Max Vo2 = maximal 
oxygen consumption; MPAP = mean pulmonary artery pressure; NYHA = New 
York Heart Association; PAD - pulmonary artery diastolic pressure; PAS = 
pulmonary artery systolic pressure; PCWP = pulmonary capillary wedge pres- 
sure; RAP = right atrial pressure; SCD = sudden cardiac death; VT = 
ventricular tachycardia. 
quired repeated hospital admissions for heart failure. Ventric- 
ular tachycardia was considered nonsustained if it was -<30 s in 
duration and terminated spontaneously and sustained if it was 
>30 s in duration with or without hemodynamic compromise. 
Statistieal analysis. Univariate and stepwise forward mul- 
tivariate logistic regression analysis were used to assess the 
association of baseline patient characteristics with cardiac 
survival and need for heart transplantation. Kaplan-Meier 
survival curves were calculated for the total cohort and for 
specific combinations of characteristics after dichotomization 
of continuous variables. Survival curves were compared using 
the Mantel-Haenszel log-rank test. Results are expressed as 
mean value _+ SE for survival analyses and mean _+ SD for 
baseline patient characteristics. A p value <0.05 was consid- 
ered significant. Logistic regression was performed using the 
software package SPSS for Windows, Release 5 (SPSS Inc, 
Chicago, IL), and Kaplan-Meier survival curves were calcu- 
lated using Abacus Concepts, Stat View. 
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Figure 2. Four-year ctuarial survival rate and 4-year actuarial free- 
dom from listing for heart ransplantation in the total study group. 
Resu l ts  
Baseline characteristics. Baseline characteristics of the 
study patients are shown in Table 1. Idiopathic dilated cardio- 
myopathy predominated as the etiology of heart failure in 69% 
of patients. By design, all patients had symptomatic heart 
failure despite treatment and had marked left ventrieular 
systolic dysfunction as demonstrated by a mean left ventricular 
ejection fraction of 20 _+ 7%. Treatment included angiotensin- 
converting enzyme inhibitors in 96% of patients and digoxin or 
diuretic drugs, or both, in >80%. Of 11 patients (10%) with a 
history of sustained ventricular tachycardia orsudden death, 4 
subsequently underwent implantation of a cardioverter- 
defibrillator. Maximal oxygen consumption was relatively well 
preserved (mean 17.4 _+ 4.3 ml/min per kg). Under optimal 
medical treatment, right heart pressures were only mildly 
elevated, and cardiac output index was not severely depressed. 
Follow-up events. During a mean follow-up period of 
25.0 _+ 14.8 months (range 4 to 58), nine deaths (8%) occurred, 
eight (7%) of which were cardiac related. Cardiac death was 
classified as sudden in seven patients and as caused by acute 
myocardial infarction in one. Only one patient died during the 
first year after evaluation. Actuarial 1- and 4-year cardiac 
survival rates for the total cohort were 98 +_ 1% and 84 _+ 7%, 
respectively (Fig. 2). No patient died of progressive heart 
failure, but nine (8%) were listed for heart transplantation 
during follow-up because of worsening heart failure symptoms. 
No patient listed for transplantation died while awaiting 
operation. Actuarial 1- and 4-year freedom from listing for 
heart ransplantation was 95 _+ 2% and 84 -- 7%, respectively, 
as shown in Figure 2. 
Predictors of cardiac death or need for transplantation. 
Results of univariate logistic regression analysis of risk factors 
are summarized in Table 2. By logistic regression analysis, 
there were no predictors for cardiac death. Longer duration of 
heart failure symptoms (p < 0.02, 37 _+ 27vs. 17 -- 20 months), 
higher mean pulmonary artery pressure (p < 0.05, 33 +- 8 vs. 
24 _+ 12 mm Hg) and higher pulmonary artery systolic (p < 
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Table 2. Univariate Logistic Regression Analysis: Predictors of Cardiac Death and Need for Heart Transplantation 
Cardiac Death Heart Transplantation 
No. of p p 
Variable Pts B + SE Value B _+ SE Value 
Age at evaluation (yr) 113 -0.01 _+ 0.04 0.75 0.01 _+ 0.34 0.88 
Gender 113 -0.06 _+ 0.85 0.94 -2.44 +_ 0.35 0.80 
NYHA functional class 113 -0.67 _+ 0.72 0.35 1.74 _+ 0.89 0.051 
Etiology of heart failure: CAD/IDCM I I 3 0.60 -- 0.76 0.43 -0.21 _+ 0.83 0.81 
Symptom duration (too) 113 -0.02 - 0.2 0.41 0.03 _+ 0.01 0.013' 
Amiodarone 113 0.69 _+ 1.14 0.54 0.55 _+ 1.13 0.63 
Class I antiarrhythmic agents 113 1.15 _+ 0.88 0.19 -6.88 _+ 28.76 0.81 
Hx of sustained VT/SCD 113 0.85 _+ 0.77 0.27 0.72 _+ 0.77 0.35 
Atrial fibrillation 113 0.55 _+ 0.86 0.53 -7.96 _+ 37.69 0.83 
ICD 113 -5.68 _+ 27.03 0.83 1.14 + 1.18 0.33 
LVEF 97 -0.04 _+ 0.06 0.56 1.34 _+ 0.25 0.25 
RAP (ram Hg) 83 0.ll _+ 0.15 0.46 0.02 + 0.17 0.92 
PAS (ram Hg) 96 -0.01 + 0.03 0.71 0.07 _+ 0.03 0.014' 
PAD (ram Hg) 95 -0.05 -- 0.05 0.93 0.07 _+ 0.05 0.047* 
MPAP (ram Hg) 85 -0.01 -- 0.04 0.84 0.05 + 0.03 0.049* 
PCWP (ram Hg) 98 -0.05 _+ 0.05 0.32 0.06 + 0.03 0.097 
Cardiac index (1/min.m 2) 87 0.27 _+ 0.48 0.58 0.10 _+ 0.46 0.83 
Max Vo2 (ml/min per kg) 99 -0.04 + 0.09 0.62 0.06 + 0.09 0.52 
*<0.05, by univariate actuarial regression; because no correction for multiplicity was used, p values hould be regarded conservatively. B = regression coefficient; 
Pts = patients; other abbreviations as in Table 1. 
0.14, 46 _+ 13 vs. 35 _+ 15 mm Hg) and diastolic pressures (p < 
0.05, 24 _+ 6 vs. 16 _+ 9 mm Hg) were significantly correlated 
with requirement for transplantation byunivariate analysis. By 
multivariate stepwise forward analysis, duration of symptoms 
(p < 0.015) and pulmonary artery systolic pressure (p < 0.004) 
remained the predictors of subsequent eed for heart trans- 
plantation. Actuarial survival without listing for heart trans- 
plantation was significantly lower for duration of heart failure 
>1 year than for <-1 year (Fig. 3). However, these results 
should be interpreted cautiously in light of the few occurrences 
of cardiac death and listing for transplantation a d the weak 
association found. 
Figure 3. Comparison of 4-year actuarial freedom from listing for 
heart transplantation i patients with symptoms of congestive heart 
failure (CHF) -<12 versus >12 months. 
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Discuss ion  
Survival in patients with heart failure. Patients with severe 
left ventricular dysfunction and symptomatic heart failure are 
known to have a poor prognosis (9-12). Recent large-scale 
clinical trials in nonselected patient populations treated with 
diuretic drugs, digoxin and angiotensin-converting enzyme 
inhibitors have demonstrated a 2-year mortality rate of -20% 
(Studies of Left Ventricular Dysfunction [SOLVD] trial [5], 
Vasodilator Heart Failure Trial II IV-HeFt II] [13]). Patients 
in the Prospective Randomized Milrinone Survival Evaluation 
(PROMISE) (14) and Cooperative North Scandinavian Ena- 
lapril Survival Study (CONSENSUS) (6) trials (with a higher 
proportion of New York Heart Association class III and IV 
heart failure) had an annual mortality rate >30%. After heart 
transplantation, the expected mortality rate in the first year 
approaches 20% (15), with subsequent 5- and 10-year mortality 
rates -30% and 50%, respectively (15). This apparent survival 
benefit has led to increasing pressure to accept patients with 
symptoms of heart failure and documented evidence of severe 
left ventricular dysfunction for active placement on the waiting 
list for heart ransplantation. These patients are often referred 
after the first recurrent episode of severe decompensated heart 
failure on the assumption that their disease will follow an 
inexorable deterioration and that death within 1 to 2 years is 
inevitable without heart ransplantation. A previous two-center 
study (8) that evaluated survival in patients referred for heart 
transplantation but treated medically, demonstrated an espe- 
cially poor prognosis (1-year survival rate of 46%). Unlike 
the patients in that study, our patients were managed in 
the current treatment era with angiotensin-converting 
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enzyme inhibitors, low use of antiarrythmic agents (except 
amiodarone--not used previously) and meticulous follow-up. 
Characteristics of study patients. Compared with the heart 
failure population in trials such as SOLVD (5) and V-HeFt II 
(13), the survival rate for patients followed up in our study was 
96% over 2 years, whereas that for angiotensin-converting 
enzyme inhibitor-treated patients in the SOLVD trial (5) was 
79% and 82% in V-Heft II (13) over 2 years. Greater survival 
was observed in our patients despite a lower ejection frac- 
tion (20% vs. 25% and 29% for SOLVD and V-HeFt II, 
respectively). Although our patients remained symptomatic on 
angiotensin-converting enzyme inhibitor therapy, they were 
relatively oung, highly motivated, drug compliant and free of 
comorbid conditions. Thus, patients with heart failure who do 
not have characteristics that exclude them from transplant 
candidate status are a select group with a markedly better 
survival rate than that of the heart failure population as a 
whole. Although the results of medical therapy in our patients 
appear superior to any published survival data after heart 
transplantation, a true comparison of survival; relative costs of 
therapy, including subsequent hospital admissions; and num- 
ber of patients who subsequently cross over to a transplant 
group can only be compared through a randomized clinical 
trial. Our data do provide criteria for randomization of pa- 
tients with clinically stable symptoms with a maximal oxygen 
uptake ->13 ml/min per kg irrespective of ejection fraction 
between heart transplantation and optimal medical therapy. 
Traditional factors thought o influence prognosis in patients 
with heart failure were not found useful in our patients and 
were not used in the decision ot to list for heart transplanta- 
tion. For instance, ejection fraction has often emerged as an 
important predictor of survival (16-18) but is not useful in a 
patient group partially characterized by the presence of a very 
low ejection fraction. Pulmonary artery pressure and duration 
of symptoms did correlate significantly with listing for heart 
transplantation because of deterioration but is of limited 
usefulness in clinical decision making in an individual patient. 
Very few deaths occurred in our patients during the subse- 
quent follow-up period of up to 58 months, and no prognostic 
indicators for subsequent mortality were detected. 
Medical management of heart transplant candidates. Pa- 
tients in our study were selected for medical therapy on the 
basis of assessment of clinical criteria and degree of clinical 
stability that could be achieved after a period of intensive 
medical therapy and education. All patients were instructed to 
reduce sodium intake to <2 g/day and were generally treated 
with high dose angiotensin-converting e zyme inhibitors. Di- 
uretic drugs were given in a dose to prevent he signs of right- 
and left-sided fluid retention. Meticulous attention was given 
to potassium replacement with a target serum potassium 
concentration >4.5 mEq/liter. Most were initially seen at 
frequent intervals in a dedicated heart failure outpatient clinic. 
Maximal oxygen uptake determinations were made after this 
period of intensification oftherapy. Right heart catheterization 
data were also obtained at a time when the patients were 
clinically stable and not at the time of initial referral or during 
decompensation. We believe that this approach is similar to 
that described by Mancini et al. (19) who stratified survival in 
a similar patient group referred for heart transplantation 
according to maximal oxygen uptake data during exercise. Our 
finding of a favorable prognosis in this patient group also lends 
support o the guidelines for transplantation (20,21), which 
also used the maximal achieved oxygen uptake as an important 
variable to determine the indication for listing for heart 
transplantation. At our center the majority of patients, deemed 
good candidates with a maximal oxygen uptake (beyond their 
anaerobic threshold) <13 ml/min per kg despite optimal 
outpatient management were accepted for listing for heart 
transplantation. Some of the patients originally transferred to 
our center in acute decompensated heart failure without any 
history of prior disease, or where alcohol, amphetamines or
cocaine use may have been implicated in the development of
heart failure, may have had an improvement in ejection 
fraction. We are unable to assess the impact of this effect on 
our data because we did not routinely measure ejection 
fraction serially. Moreover, the impact of this effect is likely to 
have been small because alcoholic- or drug-abusing patients 
would not have met the criteria for inclusion in the study group 
described in this report, where all patients were considered to 
meet conventional psychosocial nd other medical criteria as 
transplant candidates. Our data provide strong support for an 
approach to patients under consideration for heart transplan- 
tation that includes a period of intensive therapy before the 
final evaluation process, where achieved exercise capacity with 
measurement of gas exchange appears to provide a way of 
separating a patient group with an acceptable quality of life 
and a relatively good prognosis without heart transplantation. 
Stevenson (22) has advocated a similar approach but with an 
emphasis on the response to "tailored therapy" during a period 
of invasive hemodynamic monitoring. In our patients most of 
the intensification of therapy and patient education took place 
through a dedicated outpatient (heart failure) clinic over a 
period of weeks or months. With these favorable characteris- 
tics no patient in this group died of progressive heart failure. 
Study limitations. The study is limited by the relatively 
small number of patients but does nevertheless represent the 
longest study of potential transplant candidates prospectively 
identified at the time of initial evaluation as suitable for 
medical management. Sudden cardiac death, although the 
major cause of death in our study, remains comparatively rare 
over a mean follow up period of 4 years. The small number of 
patients who developed progressive symptoms could be safely 
listed for heart transplantation without mortality during the 
waiting period. 
Conclusions. Medical therapy, coupled with close supervi- 
sion directed by heart failure specialists, offers survival that 
may be better than early listing for heart transplantation. This 
approach should have a beneficial effect on the waiting time for 
patients listed for heart ransplantation, which is now >2 years 
in certain patient categories (23). Mortality among a selected 
group of sicker patients who require transplantation, and the 
number of these patients on waiting lists who are deteriorating 
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to urgent Status I (inpatient) prioritization, should be reduced, 
and perhaps most important, heart transplantation with its 
attendant morbidity, cost and limited availability reserved for 
the sickest patients. 
We thank Byron Brown, PhD, for statistical advice. 
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